全文获取类型
收费全文 | 31565篇 |
免费 | 2157篇 |
国内免费 | 1266篇 |
专业分类
耳鼻咽喉 | 328篇 |
儿科学 | 452篇 |
妇产科学 | 470篇 |
基础医学 | 3348篇 |
口腔科学 | 747篇 |
临床医学 | 2479篇 |
内科学 | 4787篇 |
皮肤病学 | 352篇 |
神经病学 | 1543篇 |
特种医学 | 1708篇 |
外国民族医学 | 2篇 |
外科学 | 8242篇 |
综合类 | 3914篇 |
现状与发展 | 2篇 |
预防医学 | 937篇 |
眼科学 | 401篇 |
药学 | 2004篇 |
25篇 | |
中国医学 | 834篇 |
肿瘤学 | 2413篇 |
出版年
2024年 | 71篇 |
2023年 | 574篇 |
2022年 | 1105篇 |
2021年 | 1396篇 |
2020年 | 1333篇 |
2019年 | 1208篇 |
2018年 | 1221篇 |
2017年 | 1025篇 |
2016年 | 960篇 |
2015年 | 1075篇 |
2014年 | 2058篇 |
2013年 | 2029篇 |
2012年 | 1856篇 |
2011年 | 2142篇 |
2010年 | 1740篇 |
2009年 | 1797篇 |
2008年 | 1878篇 |
2007年 | 1823篇 |
2006年 | 1495篇 |
2005年 | 1371篇 |
2004年 | 1087篇 |
2003年 | 938篇 |
2002年 | 742篇 |
2001年 | 568篇 |
2000年 | 448篇 |
1999年 | 388篇 |
1998年 | 314篇 |
1997年 | 269篇 |
1996年 | 235篇 |
1995年 | 223篇 |
1994年 | 183篇 |
1993年 | 164篇 |
1992年 | 135篇 |
1991年 | 126篇 |
1990年 | 112篇 |
1989年 | 74篇 |
1988年 | 82篇 |
1987年 | 77篇 |
1986年 | 69篇 |
1985年 | 86篇 |
1984年 | 83篇 |
1983年 | 45篇 |
1982年 | 65篇 |
1981年 | 51篇 |
1980年 | 58篇 |
1979年 | 35篇 |
1978年 | 34篇 |
1977年 | 32篇 |
1976年 | 30篇 |
1974年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
3.
4.
5.
6.
Jeffrey J. Silbiger 《Echocardiography (Mount Kisco, N.Y.)》2019,36(5):954-957
Secondary tricuspid regurgitation (TR) caused by right ventricular enlargement in the setting of left heart disease/pulmonary hypertension has been well described. In contrast, that associated with right atrial enlargement—atrial functional TR (AF‐TR)—remains largely underappreciated. AF‐TR most often occurs in the setting of lone atrial fibrillation, although it is also seen in its absence (idiopathic AF‐TR). Several recent studies have found that the prevalence, hemodynamic significance, and prognosis of AF‐TR are not inconsequential, suggesting increased physician awareness of this novel clinical entity is warranted. This article discusses the pathogenesis, echocardiographic findings, and treatment of this underappreciated cause of secondary TR. 相似文献
7.
《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2019,13(2):1005-1010
BackgroundWhile hyperglycemia has a key role in the pathogenesis of microvascular complications of diabetes, it is just one of the many factors contributing to macrovascular damage. The aim of the present study is to investigate the link between serum pentosidine and sRAGE levels and vascular complications in patients with prediabetes compared to normal glucose tolerance controls with obesity.MethodsIn this study were included 76 patients with mean age 50.7 ± 10.7 years, divided into two age and BMI-matched groups – group 1 with obesity without glycemic disturbances (n = 38) and group 2 with obesity and prediabetes (n = 38).ResultsThere was no significant difference in pentosidine and sRAGE levels between patients with obesity and prediabetes. Patients with hypertension had lower levels of sRAGE compared to nonhypertensive subjects. sRAGE showed a weak negative correlation to blood glucose on 60th min of OGTT and HOMA index. There was no correlation between sRAGE and pentosidine levels and the markers of micro- and macrovascular complications. There was no difference in sRAGE and pentosidine levels between patients with and without endothelial dysfunction.Conclusions: sRAGE and pentosidine levels are similar in patients with obesity with and without prediabetes and do not correlate to the markers of micro- and macrovascular complications. 相似文献
8.
Yang Liu Yanyan Gao Hengliang Liu Qi Chen Jinrui Ji Kailong Jia 《Arquivos brasileiros de cardiologia》2021,116(2):229
BackgroundDual antiplatelet therapy (DAPT) is the cornerstone treatment of acute myocardial infarction (AMI).ObjectiveThe present study aimed to investigate the efficacy and safety of triple antiplatelet therapy (TAPT) in elderly female patients with diabetes and ST segment elevation myocardial infarction (STEMI), who had undergone percutaneous coronary intervention (PCI).MethodsWe designed a randomized, single-blind study. Control group A (97 elderly male patients with diabetes and STEMI, whose CRUSADE scores were < 30) received aspirin, ticagrelor, and tirofiban. A total of 162 elderly female patients with diabetes and STEMI were randomly divided into two groups according to CRUSADE score. Group B (69 patients with CRUSADE score > 31) received aspirin and ticagrelor. Group C (93 patients with CRUSADE score < 30) received aspirin, ticagrelor and tirofiban. P values < 0.05 were considered statistically significant.ResultsCompared to the findings in group A, post-PCI Thrombolysis in Myocardial Infarction (TIMI) grade 3 blood flow and TIMI myocardial perfusion grade 3 were significantly less prevalent in group B (p < 0.05). When compared to groups A and C, the incidence of major adverse complications was significantly higher in group B (p < 0.05).ConclusionTAPT could effectively reduce the incidence of major complications in elderly female patients with diabetes and STEMI. However, close attention should be paid to hemorrhage in patients receiving TAPT. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0) 相似文献
9.
10.